Answers are grounded in this paper and cite their sources.
Introduction Duvelisib, a dual phosphatidylinositol 3-kinase (PI3K)-δ/γ inhibitor, is used for relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), but serious safety concerns warrant continued post-marketing surveillance. Methods We analyzed the FDA Adverse Event Reporting System (FAERS) from the third quarter of 2018 through the second quarter of 2026. Duvelisib-associated adverse events (AEs) were evaluated using disproportionality analysis and clinical priority scoring. Serious vs. non-serious AE patterns, subgroup differences, factors associated with serious AE (SAE) reporting, and comparative reporting disproportionality vs. ofatumumab were also assessed. Results Among 11,580,309 FAERS reports, 703 duvelisib-associated reports were included. Death was the only strong-priority signal, while pneumonia, sepsis, enterocolitis, colitis, and diarrhoea were classified as moderate-priority signals. Infectious enteritis showed the highest disproportionality (ROR025 = 49.63) but was based on only six reports and received weak clinical priority. Among reports with death recorded as an outcome, significant SAE signals included colitis, stomatitis, dehydration, hepatic failure, diarrhoea, and pneumonia. Subgroup analyses showed disproportionate SAE reporting among patients aged <65 years, reports from North America, T-cell lymphoma, and non-healthcare professional reporters. However, these findings should be interpreted cautiously given substantial missing demographic information, particularly for age, and potential differences in reporting practices, and should not be interpreted as evidence of differential susceptibility. Comparative analysis with ofatumumab showed higher reporting disproportionality for several clinically relevant events, including death and colitis. Conclusion This study identified and clinically prioritized duvelisib-associated safety signals, distinguishing established safety concerns from less well-characterized signals requiring further investigation. These findings support continued post-marketing evaluation of duvelisib while recognizing that FAERS signals reflect reporting disproportionality rather than incidence or causal risk.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: